p53 regulatory protein called RB18A and uses thereof

Abstract

This invention relates to a new protein called RB18A for “Recognized By PAb1801 moAntibody”, which is a p53 regulatory protein, to the nucleotide sequence encoding said protein, and to the diagnostic and therapeutic applications thereof, in particular for the diagnosis, prevention or treatment of neoplasia.

1 . An isolated antibody which is capable of specifically recognizing a RB18A polypeptide having the amino acid sequence of SEQ ID No.2.  
     
     
         2 . An isolated antibody which is capable of specifically recognizing a polypeptide comprising a sequence selected from the group consisting of a fragment from amino acid 436 to amino acid 1566 of SEQ ID No. 2, a fragment from amino acid 436 to amino acid 1228 of SEQ ID No. 2, a fragment from amino acid 436 to amino acid 927 of SEQ ID No. 2, a fragment from amino acid 1537 to amino acid 1566 of SEQ ID No. 2, a fragment from amino acid 1234 to amino acid 1566 of SEQ ID No. 2, a fragment from amino acid 1234 to amino acid 1406 of SEQ ID No. 2, a fragment from amino acid 927 to amino acid 1406 of SEQ ID No.2.  
     
     
         3 . An isolated antibody which is capable of specifically recognizing a polypeptide having an amino acid sequence that: 
 differs from SEQ ID No.2 only by substitution of one or more amino acids;    shows at least 90% identity with SEQ ID No. 2; and    exhibits substantially the same biological property as a polypeptide of SEQ ID No. 2, with regard to DNA binding, homooligomerization, binding to p53 and/or activation of a sequence specific DNA binding function of p53.    
     
     
         4 . A pharmaceutical composition comprising an antibody according to  claim 1 , in association with a pharmaceutically acceptable carrier.  
     
     
         5 . A pharmaceutical composition comprising an antibody according to  claim 2 , in association with a pharmaceutically acceptable carrier.  
     
     
         6 . A pharmaceutical composition comprising an antibody according to  claim 3 , in association with a pharmaceutically acceptable carrier.